MAPT and Alzheimer disease: The present study assessed the neuroprotective effects of DRB (a CK2 inhibitor) and Hesperidin in the in vitro AD model using the MTT assay for cell viability, RT-qPCR analysis for gene expression levels of model markers (CK2α, ADAM10, and BACE1), and ELISA for Aβ1–42, phospho-Tau (T181), and apoptotic (Bax and Bcl-2) proteins.